GeneDx Faces Securities Fraud Lawsuit Over Impairment Disclosures

The complaint filed against the NASDAQ-listed company claims that GeneDx misled the market throughout the class period. The legal action follows the firm's Q1 2026 financial report released on May 4, 2026, which revealed a sharp decline in adjusted gross margins and a $31.3 million impairment tied to Fabric Genomics. Plaintiffs argue these disclosures corrected previous, materially misleading public statements regarding the company's financial health, causing significant investor losses once the reality of the impairment emerged.

Schall Brown & Schwartz LLP, the firm representing the potential class, is inviting shareholders to contact partners Brian Schall and David Schwartz to discuss eligibility for recovery. While the class has not yet received formal certification, affected investors may participate as lead plaintiffs or remain absent members until the legal proceedings conclude. Interested parties can reach the firm at their Los Angeles office or via their online portal for a consultation regarding their rights and potential compensation.